Drug Profile
Research programme: antibacterials - Achaogen
Alternative Names: Achaogens; ACHN-978; AKAO-Lpxc; LpxC inhibitors - Achaogen; SOS pathway inhibitors - AchaogenLatest Information Update: 26 Mar 2018
Price :
$50
*
At a glance
- Originator Achaogen
- Class Antibodies; Immunoglobulin fragments; Monoclonal antibodies; Peptides; Proteins; Small molecules
- Mechanism of Action LpxC inhibitors; SOS response inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anthrax; Bacterial infections; Escherichia coli infections; Pseudomonal infections; Yersinia infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anthrax in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 15 Mar 2016 Achaogen has patents pending for anti-pseudomonal LpxC inhibitor compounds in USA, Canada, China, Europe, Hong Kong, India, Japan, and Taiwan (Achaogen, Form 10-K, March 2016)